Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04645602 · ClinicalTrials.gov registry record · Early Phase 1
Merck IIT: RRP Pembro and Lenvatinib
A Early Phase 1 study of Human Papilloma Virus and Pulmonary Disease, sponsored by Yale University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04645602 is a Early Phase 1 study of Human Papilloma Virus and Pulmonary Disease that is actively recruiting participants, run by Yale University. The registered enrollment target is 20 participants, below the 623-participant average among 26 other Human Papilloma Virus trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04645602, a Early Phase 1 study of Human Papilloma Virus and Pulmonary Disease, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying Lenvatinib in combination with Pembrolizumab in people with human papillomavirus (HPV)-associated recurrent respiratory papillomatosis (RRP). The names of the study drugs involved in this study are: * Pembrolizumab * Lenvatinib
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Lenvatinib
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-07-18 |
| Est. Completion | 2027-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04645602
The ClinicalTrials.gov registry entry for NCT04645602 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 623-participant average among 26 other Human Papilloma Virus trials with a reported enrollment target (97% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Human Papilloma Virus appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04645602 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT04645602 about?
NCT04645602 is a clinical study titled "Merck IIT: RRP Pembro and Lenvatinib". This research study is studying Lenvatinib in combination with Pembrolizumab in people with human papillomavirus (HPV)-associated recurrent respiratory papillomatosis (RRP). The names of the study drugs involved in this study are: * Pembrolizumab * Lenvatinib
What is the current status of trial NCT04645602?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2025-07-18. Estimated completion is 2027-12.
What conditions does trial NCT04645602 study?
This clinical trial studies the following conditions: Human Papilloma Virus, Pulmonary Disease, Recurrent Respiratory Papillomatosis.
What interventions are being tested in trial NCT04645602?
The interventions under investigation include: Pembrolizumab (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT04645602?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04645602 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old
ACTIVE NOT RECRUITING · Early Phase 1
-
Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
RECRUITING · NA
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma
RECRUITING
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.